{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:15:55Z","timestamp":1757618155799,"version":"3.44.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100001797","name":"Pharmaceutical Research and Manufacturers of America Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001797","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000056","name":"National Institute of Nursing Research","doi-asserted-by":"crossref","award":["K23NR019296"],"award-info":[{"award-number":["K23NR019296"]}],"id":[{"id":"10.13039\/100000056","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01CA236871"],"award-info":[{"award-number":["R01CA236871"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00520-025-09618-z","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T08:43:55Z","timestamp":1749113035000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk factors, behaviors, and adverse health outcomes of financial toxicity in adult chronic myeloid leukemia survivors: a theory-based structural equation model"],"prefix":"10.1007","volume":"33","author":[{"given":"Ruiqi","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudeshna","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah M.","family":"Belcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinbing","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilana","family":"Graetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony M.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily J.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine A.","family":"Yeager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"9618_CR1","doi-asserted-by":"publisher","unstructured":"Deininger MW, Shah NP, Altman JK, et al. Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. Oct 1 2020;18(10):1385\u20131415. https:\/\/doi.org\/10.6004\/jnccn.2020.0047","DOI":"10.6004\/jnccn.2020.0047"},{"key":"9618_CR2","doi-asserted-by":"publisher","unstructured":"Minciacchi VR, Kumar R, Krause DS. Chronic myeloid leukemia: a model disease of the past, present and future. Cells. Jan 10 2021;10(1)https:\/\/doi.org\/10.3390\/cells10010117","DOI":"10.3390\/cells10010117"},{"key":"9618_CR3","doi-asserted-by":"publisher","unstructured":"De SK. Asciminib: First FDA approved allosteric inhibitor of BCR-ABL1 for the treatment of chronic myeloid leukemia. Medicinal Chemistry Research. 2023\/03\/01 2023;32(3):424\u2013433. https:\/\/doi.org\/10.1007\/s00044-022-03011-9","DOI":"10.1007\/s00044-022-03011-9"},{"issue":"9","key":"9618_CR4","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1182\/blood-2011-08-358135","volume":"119","author":"H Kantarjian","year":"2012","unstructured":"Kantarjian H, O\u2019Brien S, Jabbour E et al (2012) Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 119(9):1981\u20131987. https:\/\/doi.org\/10.1182\/blood-2011-08-358135","journal-title":"Blood"},{"issue":"23","key":"9618_CR5","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1002\/cncr.35038","volume":"129","author":"K Sasaki","year":"2023","unstructured":"Sasaki K, Haddad FG, Short NJ et al (2023) Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-the Surveillance, Epidemiology, and End Results database, 2000\u20132019. Cancer 129(23):3805\u20133814. https:\/\/doi.org\/10.1002\/cncr.35038","journal-title":"Cancer"},{"issue":"5","key":"9618_CR6","doi-asserted-by":"publisher","first-page":"e443","DOI":"10.1200\/JOP.19.00301","volume":"16","author":"AL Cole","year":"2020","unstructured":"Cole AL, Wood WA Jr, Muluneh B, Lund JL, ElstonLafata J, Dusetzina SB (2020) Comparative safety and health care expenditures among patients with chronic myeloid leukemia initiating first-line imatinib dasatinib or nilotinib. JCO Oncol Pract 16(5):e443\u2013e455. https:\/\/doi.org\/10.1200\/JOP.19.00301","journal-title":"JCO Oncol Pract"},{"issue":"3","key":"9618_CR7","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.1200\/OP.20.00143","volume":"17","author":"JJ Wilkes","year":"2021","unstructured":"Wilkes JJ, Lyman GH, Doody DR et al (2021) Health care cost associated with contemporary chronic myelogenous leukemia therapy compared with that of other hematologic malignancies. JCO Oncol Pract 17(3):e406\u2013e415. https:\/\/doi.org\/10.1200\/OP.20.00143","journal-title":"JCO Oncol Pract"},{"issue":"11","key":"9618_CR8","doi-asserted-by":"publisher","first-page":"e1811","DOI":"10.1200\/OP.20.00967","volume":"17","author":"B Talon","year":"2021","unstructured":"Talon B, Calip GS, Lee TA, Sharp LK, Patel P, Touchette DR (2021) Trend in tyrosine kinase inhibitor utilization, price, and out-of-pocket costs in patients with chronic myelogenous leukemia. JCO Oncol Pract 17(11):e1811\u2013e1820. https:\/\/doi.org\/10.1200\/OP.20.00967","journal-title":"JCO Oncol Pract"},{"issue":"5","key":"9618_CR9","doi-asserted-by":"publisher","first-page":"e622","DOI":"10.1111\/hsc.12808","volume":"27","author":"C Coumoundouros","year":"2019","unstructured":"Coumoundouros C, Ould Brahim L, Lambert SD, McCusker J (2019) The direct and indirect financial costs of informal cancer care: a scoping review. Health Soc Care Community 27(5):e622\u2013e636. https:\/\/doi.org\/10.1111\/hsc.12808","journal-title":"Health Soc Care Community"},{"key":"9618_CR10","doi-asserted-by":"publisher","unstructured":"Ghazal LV, Gormley M, Merriman JD, Santacroce SJ. Financial toxicity in adolescents and young adults with cancer: a concept analysis. Cancer Nurs. Nov-Dec 01 2021;44(6):E636-E651. https:\/\/doi.org\/10.1097\/NCC.0000000000000972","DOI":"10.1097\/NCC.0000000000000972"},{"issue":"9","key":"9618_CR11","doi-asserted-by":"publisher","first-page":"5523","DOI":"10.1007\/s00520-021-06084-1","volume":"29","author":"EC Dee","year":"2021","unstructured":"Dee EC, Nipp RD, Muralidhar V et al (2021) Financial worry and psychological distress among cancer survivors in the United States, 2013\u20132018. Support Care Cancer 29(9):5523\u20135535. https:\/\/doi.org\/10.1007\/s00520-021-06084-1","journal-title":"Support Care Cancer"},{"issue":"5","key":"9618_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1188\/19.CJON.S2.5-13","volume":"23","author":"T Thomas","year":"2019","unstructured":"Thomas T, Hughes T, Mady L, Belcher SM (2019) Financial toxicity: a review of the literature and nursing opportunities. Clin J Oncol Nurs 23(5):5\u201313. https:\/\/doi.org\/10.1188\/19.CJON.S2.5-13","journal-title":"Clin J Oncol Nurs"},{"issue":"2","key":"9618_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3322\/caac.21443","volume":"68","author":"PM Carrera","year":"2018","unstructured":"Carrera PM, Kantarjian HM, Blinder VS (2018) The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin 68(2):153\u2013165. https:\/\/doi.org\/10.3322\/caac.21443","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"9618_CR14","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1200\/JCO.2015.64.6620","volume":"34","author":"SD Ramsey","year":"2016","unstructured":"Ramsey SD, Bansal A, Fedorenko CR et al (2016) Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol 34(9):980\u2013986. https:\/\/doi.org\/10.1200\/JCO.2015.64.6620","journal-title":"J Clin Oncol"},{"issue":"1","key":"9618_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/1043454218810137","volume":"36","author":"SJ Santacroce","year":"2019","unstructured":"Santacroce SJ, Kneipp SM (2019) A conceptual model of financial toxicity in pediatric oncology. J Pediatr Oncol Nurs Jan\/Feb 36(1):6\u201316. https:\/\/doi.org\/10.1177\/1043454218810137","journal-title":"J Pediatr Oncol Nurs Jan\/Feb"},{"issue":"12","key":"9618_CR16","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.clml.2020.08.009","volume":"20","author":"H Bostan","year":"2020","unstructured":"Bostan H, Toptas T, Tanrikulu FP et al (2020) Quality of life and symptom burden with first- and second-generation tyrosine kinase inhibitors in patients with chronic-phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 20(12):836\u2013842. https:\/\/doi.org\/10.1016\/j.clml.2020.08.009","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"9618_CR17","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.3390\/curroncol29060305","volume":"29","author":"C Parker","year":"2022","unstructured":"Parker C, Berkovic D, Ayton D, Zomer E, Liew D, Wei A (2022) Patient perceived financial burden in haematological malignancies: a systematic review. Curr Oncol 29(6):3807\u20133824. https:\/\/doi.org\/10.3390\/curroncol29060305","journal-title":"Curr Oncol"},{"issue":"5","key":"9618_CR18","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1182\/blood-2013-01-477687","volume":"122","author":"LA Williams","year":"2013","unstructured":"Williams LA, Garcia Gonzalez AG, Ault P et al (2013) Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood 122(5):641\u2013647. https:\/\/doi.org\/10.1182\/blood-2013-01-477687","journal-title":"Blood"},{"issue":"5","key":"9618_CR19","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/nur.22069","volume":"43","author":"KA Yeager","year":"2020","unstructured":"Yeager KA, Waldrop-Valverde D, Paul S et al (2020) Adherence trajectories in oral therapy for chronic myeloid leukemia: overview of a research protocol. Res Nurs Health 43(5):443\u2013452. https:\/\/doi.org\/10.1002\/nur.22069","journal-title":"Res Nurs Health"},{"issue":"1","key":"9618_CR20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/0049124187016001004","volume":"16","author":"PM Bentler","year":"1987","unstructured":"Bentler PM, Chou C-P (1987) Practical issues in structural modeling. Sociol Methods Res 16(1):78\u2013117. https:\/\/doi.org\/10.1177\/0049124187016001004","journal-title":"Sociol Methods Res"},{"issue":"20","key":"9618_CR21","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1002\/cncr.28814","volume":"120","author":"JA de Souza","year":"2014","unstructured":"de Souza JA, Yap BJ, Hlubocky FJ et al (2014) The development of a financial toxicity patient-reported outcome in cancer: the COST measure. Cancer 120(20):3245\u20133253. https:\/\/doi.org\/10.1002\/cncr.28814","journal-title":"Cancer"},{"issue":"10","key":"9618_CR22","doi-asserted-by":"publisher","first-page":"6109","DOI":"10.1007\/s00520-020-05962-4","volume":"29","author":"MSN Ng","year":"2021","unstructured":"Ng MSN, Choi KC, Chan DNS et al (2021) Identifying a cut-off score for the cost measure to indicate high financial toxicity and low quality of life among cancer patients. Support Care Cancer 29(10):6109\u20136117. https:\/\/doi.org\/10.1007\/s00520-020-05962-4","journal-title":"Support Care Cancer"},{"key":"9618_CR23","unstructured":"Agency for Healthcare Research and Quality. The Medical Expenditure Panel Survey (MEPS). https:\/\/www.meps.ahrq.gov\/mepsweb\/"},{"key":"9618_CR24","doi-asserted-by":"publisher","unstructured":"Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. Sep 2014;106(9)https:\/\/doi.org\/10.1093\/jnci\/dju244","DOI":"10.1093\/jnci\/dju244"},{"issue":"12","key":"9618_CR25","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1007\/s11136-016-1333-3","volume":"25","author":"A Mutebi","year":"2016","unstructured":"Mutebi A, Slack M, Warholak TL, Hudgens S, Coons SJ (2016) Interpretation of verbal descriptors for response options commonly used in verbal rating scales in patient-reported outcome instruments. Qual Life Res 25(12):3181\u20133189. https:\/\/doi.org\/10.1007\/s11136-016-1333-3","journal-title":"Qual Life Res"},{"key":"9618_CR26","doi-asserted-by":"publisher","unstructured":"Bai J, Bruner DW, Fedirko V, et al. Gut microbiome associated with the psychoneurological symptom cluster in patients with head and neck cancers. Cancers (Basel). Sep 6 2020;12(9)https:\/\/doi.org\/10.3390\/cancers12092531","DOI":"10.3390\/cancers12092531"},{"issue":"3","key":"9618_CR27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"G EuroQol","year":"1990","unstructured":"EuroQol G (1990) EuroQol\u2013a new facility for the measurement of health-related quality of life. Health Policy 16(3):199\u2013208. https:\/\/doi.org\/10.1016\/0168-8510(90)90421-9","journal-title":"Health Policy"},{"issue":"2","key":"9618_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.5152\/eurjrheum.2020.19043","volume":"7","author":"JJB Seng","year":"2020","unstructured":"Seng JJB, Kwan YH, Fong W et al (2020) Validity and reliability of EQ-5D-5L among patients with axial spondyloarthritis in Singapore. Eur J Rheumatol 7(2):71\u201378. https:\/\/doi.org\/10.5152\/eurjrheum.2020.19043","journal-title":"Eur J Rheumatol"},{"key":"9618_CR29","unstructured":"National Comprehensive Cancer Network. NCCN guidelines for patients: distress during cancer care. 2021"},{"issue":"15\u201316","key":"9618_CR30","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1111\/jocn.15698","volume":"30","author":"H Sousa","year":"2021","unstructured":"Sousa H, Oliveira J, Figueiredo D, Ribeiro O (2021) The clinical utility of the distress thermometer in non-oncological contexts: a scoping review. J Clin Nurs 30(15\u201316):2131\u20132150. https:\/\/doi.org\/10.1111\/jocn.15698","journal-title":"J Clin Nurs"},{"key":"9618_CR31","unstructured":"Department of Health and Human Services. 2023 poverty guidelines. https:\/\/aspe.hhs.gov\/2023-poverty-guidelines"},{"issue":"1","key":"9618_CR32","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/bioinformatics\/btr597","volume":"28","author":"DJ Stekhoven","year":"2012","unstructured":"Stekhoven DJ, Buhlmann P (2012) MissForest\u2013non-parametric missing value imputation for mixed-type data. Bioinformatics 28(1):112\u2013118. https:\/\/doi.org\/10.1093\/bioinformatics\/btr597","journal-title":"Bioinformatics"},{"key":"9618_CR33","doi-asserted-by":"publisher","unstructured":"Waljee AK, Mukherjee A, Singal AG, et al. Comparison of imputation methods for missing laboratory data in medicine. BMJ Open. Aug 1 2013;3(8)https:\/\/doi.org\/10.1136\/bmjopen-2013-002847","DOI":"10.1136\/bmjopen-2013-002847"},{"key":"9618_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v048.i02","volume":"48","author":"Y Rosseel","year":"2012","unstructured":"Rosseel Y (2012) lavaan: an R package for structural equation modeling. J Stat Softw 48:1\u201336","journal-title":"J Stat Softw"},{"key":"9618_CR35","doi-asserted-by":"crossref","unstructured":"Hu Lt, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Structural Equation Modeling: a multidisciplinary journal. 1999;6(1):1\u201355","DOI":"10.1080\/10705519909540118"},{"key":"9618_CR36","doi-asserted-by":"crossref","unstructured":"Byrne BM. Structural equation modeling with mplus: basic concepts, applications, and programming. Routledge; 2013","DOI":"10.4324\/9780203807644"},{"key":"9618_CR37","unstructured":"Kline RB. Principles and practice of structural equation modeling. Guilford publications; 2023"},{"key":"9618_CR38","doi-asserted-by":"crossref","unstructured":"Bansal A, Ramsey SD, Fedorenko CR, et al. Financial insolvency as a risk factor for mortality among patients with cancer. American Society of Clinical Oncology; 2015","DOI":"10.1200\/jco.2015.33.15_suppl.6509"},{"issue":"1","key":"9618_CR39","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00520-020-05468-z","volume":"29","author":"ES Ver Hoeve","year":"2021","unstructured":"Ver Hoeve ES, Ali-Akbarian L, Price SN, Lothfi NM, Hamann HA (2021) Patient-reported financial toxicity, quality of life, and health behaviors in insured US cancer survivors. Support Care Cancer 29(1):349\u2013358. https:\/\/doi.org\/10.1007\/s00520-020-05468-z","journal-title":"Support Care Cancer"},{"issue":"2","key":"9618_CR40","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/07347332.2020.1836547","volume":"39","author":"B Thom","year":"2021","unstructured":"Thom B, Mamoor M, Lavery JA et al (2021) The experience of financial toxicity among advanced melanoma patients treated with immunotherapy. J Psychosoc Oncol 39(2):285\u2013293. https:\/\/doi.org\/10.1080\/07347332.2020.1836547","journal-title":"J Psychosoc Oncol"},{"key":"9618_CR41","doi-asserted-by":"publisher","first-page":"e1094","DOI":"10.1200\/OP.20.00721","volume":"17","author":"C Friedes","year":"2021","unstructured":"Friedes C et al (2021) Longitudinal trends of financial toxicity in patients with lung cancer: a prospective cohort study. JCO Oncol Pract 17:e1094\u2013e1109. https:\/\/doi.org\/10.1200\/OP.20.00721","journal-title":"JCO Oncol Pract"},{"key":"9618_CR42","doi-asserted-by":"publisher","unstructured":"Parikh DA, Rodriguez GM, Ragavan M, et al. Lay healthcare worker financial toxicity intervention: a pilot financial toxicity screening and referral program. Support Care Cancer. Feb 16 2024;32(3):161. https:\/\/doi.org\/10.1007\/s00520-024-08357-x","DOI":"10.1007\/s00520-024-08357-x"},{"issue":"10","key":"9618_CR43","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.6004\/jnccn.2020.7581","volume":"18","author":"K Watabayashi","year":"2020","unstructured":"Watabayashi K, Steelquist J, Overstreet KA et al (2020) A pilot study of a comprehensive financial navigation program in patients with cancer and caregivers. J Natl Compr Canc Netw 18(10):1366\u20131373. https:\/\/doi.org\/10.6004\/jnccn.2020.7581","journal-title":"J Natl Compr Canc Netw"},{"issue":"15","key":"9618_CR44","doi-asserted-by":"publisher","first-page":"e7306","DOI":"10.1002\/cam4.7306","volume":"13","author":"H Badr","year":"2024","unstructured":"Badr H, Han J, Mims M (2024) Development and validation of FinTox: a new screening tool to assess cancer-related financial toxicity. Cancer Med 13(15):e7306. https:\/\/doi.org\/10.1002\/cam4.7306","journal-title":"Cancer Med"},{"key":"9618_CR45","doi-asserted-by":"crossref","unstructured":"Shankaran V, Carlos R, Hershman D, et al. A randomized trial addressing Cancer-Related Financial Hardship through Delivery of a Proactive Financial Navigation Intervention (CREDIT): SWOG S1912. 2022","DOI":"10.21203\/rs.3.rs-1439367\/v1"},{"issue":"2","key":"9618_CR46","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3928\/25731777-20240422-09","volume":"39","author":"ML Pratt-Chapman","year":"2024","unstructured":"Pratt-Chapman ML, Rocque G, McMahon J et al (2024) Institute for Comprehensive Cancer Care Services: the Centers for Medicare & Medicaid Services will pay for patient navigation\u2014now what? Oncol Issues 39(2):54\u201363","journal-title":"Oncol Issues"},{"issue":"31","key":"9618_CR47","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1200\/JCO.21.02400","volume":"40","author":"F Gany","year":"2022","unstructured":"Gany F, Melnic I, Wu M et al (2022) Food to overcome outcomes disparities: a randomized controlled trial of food insecurity interventions to improve cancer outcomes. J Clin Oncol 40(31):3603\u20133612. https:\/\/doi.org\/10.1200\/JCO.21.02400","journal-title":"J Clin Oncol"},{"key":"9618_CR48","unstructured":"Office of Disease Prevention and Health Promotion. Healthy people 2030, U.S. Department of Health and Human Services. https:\/\/health.gov\/healthypeople\/priority-areas\/social-determinants-health"},{"key":"9618_CR49","doi-asserted-by":"publisher","unstructured":"Altice CK, Banegas MP, Tucker-Seeley RD, Yabroff KR. Financial hardships experienced by cancer survivors: a systematic review. J Natl Cancer Inst. Feb 2017;109(2). https:\/\/doi.org\/10.1093\/jnci\/djw205","DOI":"10.1093\/jnci\/djw205"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09618-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09618-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09618-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T17:52:46Z","timestamp":1757181166000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09618-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["9618"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09618-z","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"12 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This parent study was performed in line with the principles of the Declaration of Helsinki. The parent and secondary analysis studies have received ethical approval from the Emory University Institutional Review Board (IRB) and two cancer research committees to protect participants\u2019 rights and welfare (03\/07\/2019, IRB00109411).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Consent to publish was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Author Anthony M. Hunter has received consultant honoraria from GSK, PharmaEssentia, Blueprint Medicines, Sobi (formerly CTI biopharma), and Incyte. He has also received research support from Incyte, Cogent Biosciences, Ascentage Pharma, Blueprint Medicines, Syntrix Biosystems, Novartis, and PharmaEssentia. Other authors declare they have no conflict interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"542"}}